TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29260907

Group type: EXPERIMENTAL
Intervention: Bright light (4400 lx)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control light (230 lx)
Number of subjects: 26
Study: 26773108

Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Brodalumab 280 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 24014134

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (ongoing antidiabetic therapy)
Number of subjects: 43
Study: 22218402

Group type: EXPERIMENTAL
Intervention: Immediate cessation with nicotine patch therapy (2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduction approach with either 4 mg nicotine lozenge or ST brand switching
Number of subjects: 0
Study: 19854555

Group type: EXPERIMENTAL
Intervention: Arctic Sun
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard cooling (blankets and ice packs)
Number of subjects: 64
Study: 18235213

Group type: EXPERIMENTAL
Intervention: Metamizole 2 g/8 h i.v. (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Morphine 10 mg/4 h s.c. (n = 8)
Number of subjects: 16
Study: 15905654

Group type: EXPERIMENTAL
Intervention: Experimental group (GPR method strengthening and flexibility exercises)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (conventional physical therapy protocol)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intergroup comparison
Number of subjects: 45
Study: 14608143

Group type: EXPERIMENTAL
Intervention: poly‐N‐acetylglucosamine (pGlcNAc)
Number of subjects: 0
Study: 10663966

Group type: EXPERIMENTAL
Intervention: Kainic acid (KA) administration
Number of subjects: 2
Study: 8781194

Group type: EXPERIMENTAL
Intervention: 10% carbohydrate (CHO) drink (CI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (PI)
Number of subjects: 17
Study: 1464075

Group type: EXPERIMENTAL
Intervention: 1000 mg methyl prednisolone (three pulses)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 34
Study: 2866062

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blocking drugs (atenolol, propranolol, pindolol)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Propranolol (beta 1- and beta 2-blocker)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Beta-blockers (atenolol, propranolol, pindolol)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atenolol and Propranolol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 17
Study: 31969201

Group type: EXPERIMENTAL
Intervention: Escitalopram combined with memantine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30297313

Group type: EXPERIMENTAL
Intervention: 50‐μm plus 100‐μm PVA particles (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 100‐μm PVA particles alone (group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 25863804

Group type: EXPERIMENTAL
Intervention: DEB (Drug-Eluting Balloon)
Number of subjects: 30

Group type: COMPARATOR
Intervention: BMS (Bare-Metal Stent)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: pre-DEB
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: post-DEB
Number of subjects: 30
Study: 23771989

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Free-managed diet (FD)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Weight loss (≥5%)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Weight loss categories (<5%, 5-10%, >10%)
Number of subjects: 138
Study: 23631690

Group type: EXPERIMENTAL
Intervention: Countermovement drop jump training
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Bounce drop jump training
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 21111094

Group type: EXPERIMENTAL
Intervention: Therapeutic meal group (seven diagnosis-appropriate therapeutic meals a week)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy (MNT)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: MNT plus therapeutic meals
Number of subjects: 321

Group type: COMPARATOR
Intervention: Literature control group
Number of subjects: 321
Study: 18181808

Group type: EXPERIMENTAL
Intervention: Sequential anticoagulation (citrate for the first 3.5 h, switching to 30‐min anticoagulation‐free hemodialysis)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard citrate anticoagulation
Number of subjects: 52
Study: 15902989

Group type: EXPERIMENTAL
Intervention: Chokeberry juice (150 mL daily, containing 23 mg/100 mL of anthocyanins)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 12919306

Group type: EXPERIMENTAL
Intervention: Coping styles and psychosocial variables in Graz group
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Coping styles and psychosocial variables in Jerusalem group
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Psychosocial variables affecting psychological distress
Number of subjects: 424
Study: 10048367

Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography (ICG)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fluorescein angiography (FA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography (ICG) and Fluorescein angiography (FA)
Number of subjects: 17
Study: 8948373

Group type: EXPERIMENTAL
Intervention: Bovine immunoglobulin concentrate (powder form) for 21 consecutive days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bovine immunoglobulin concentrate (capsule form)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Patients without C. parvum (cohort 3)
Number of subjects: 24
Study: 1661057

Group type: EXPERIMENTAL
Intervention: High titre varicella vaccine (5300 PFU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low titre varicella vaccine (2000 PFU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combined varicella and MMR vaccine (high titre)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combined varicella and MMR vaccine (low titre)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single varicella vaccine (both titre levels)
Number of subjects: 100
Study: 7213522

Group type: EXPERIMENTAL
Intervention: Quinidine (oral and i.v. dosing)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quinidine (i.v. dosing)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quinidine (oral dosing)
Number of subjects: 10
Study: 31740021

Group type: EXPERIMENTAL
Intervention: D2BT <90 minutes
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: D2BT >90 minutes <24 hours
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: D2BT >24 hours
Number of subjects: 1550
Study: 30535949

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28146137

Group type: EXPERIMENTAL
Intervention: Transvaginal mesh repair (TVMR)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Stapled transanal rectal resection (STARR)
Number of subjects: 39
Study: 25649214

Group type: EXPERIMENTAL
Intervention: AS replacement every 7 days
Number of subjects: 6554

Group type: COMPARATOR
Intervention: AS replacement every 4 days (control)
Number of subjects: 6554
Study: 23671213

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 61
Study: 21895677

Group type: EXPERIMENTAL
Intervention: Reinfusion of RBCs after 14 days of storage
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Reinfusion of RBCs after 28 days of storage
Number of subjects: 25
Study: 19440010

Group type: EXPERIMENTAL
Intervention: 5 ml lidocaine‐prilocaine cream perianally
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine‐prilocaine cream perianally and intrarectally
Number of subjects: 80

Group type: COMPARATOR
Intervention: No anesthesia (control group)
Number of subjects: 80
Study: 17045952

Group type: EXPERIMENTAL
Intervention: Iron mouthrinse (10mL of 10mM ferrous sulphate solution) after immersion in cola drink for 5min, followed by brushing after 1min or 30min.
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment after immersion in cola drink.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fluoride dentifrice brushing after 1min or 30min post-immersion.
Number of subjects: 10
Study: 15321811

Group type: EXPERIMENTAL
Intervention: Monoglutamyl folic acid (323 nmol/d)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Heptaglutamyl folic acid (262 nmol/d)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 11756369

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) pills
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9649716

Group type: EXPERIMENTAL
Intervention: Dithranol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate
Number of subjects: 0
Study: 7855551

Group type: EXPERIMENTAL
Intervention: Clindamycin 6.5 mg per kg body weight b.i.d. (children) or 300 mg t.i.d. (adults) for 10 days
Number of subjects: 239

Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin 12.5 mg per kg body weight b.i.d. for 10 days
Number of subjects: 239
Study: 2526622

Group type: EXPERIMENTAL
Intervention: Low dose (2 micrograms or 0.1 ml) intradermal hepatitis B vaccine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard (20 micrograms or 1 ml) intramuscular hepatitis B vaccine
Number of subjects: 32
Study: 856569

Group type: EXPERIMENTAL
Intervention: 20 mg reproterol
Number of subjects: 81

Group type: COMPARATOR
Intervention: 20 mg orciprenaline
Number of subjects: 81
Study: 31558100

Group type: EXPERIMENTAL
Intervention: Dader Method for Pharmaceutical Care (PC)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Institution's usual care
Number of subjects: 131
Study: 28601627

Group type: EXPERIMENTAL
Intervention: 0.2 μg/kg dexmedetomidine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 78
Study: 26471380

Group type: EXPERIMENTAL
Intervention: BRV 100 mg/day
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: BRV 200 mg/day
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 768
Study: 24073548

Group type: EXPERIMENTAL
Intervention: Fixed combination travoprost 0.004%/timolol 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fixed combination dorzolamide 2%/timolol 0.5%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 21791117

Group type: EXPERIMENTAL
Intervention: Single task gait training with cueing strategies to increase step length
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dual task gait training to improve step length while performing added tasks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single task gait training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dual task gait training
Number of subjects: 60
Study: 19180530

Group type: EXPERIMENTAL
Intervention: Brief self-administered psychological intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Deferred entry group (control)
Number of subjects: 46
Study: 17988323

Group type: EXPERIMENTAL
Intervention: Novel spatial particle during habituation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel word as a count noun
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel count noun
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel particle (possibly assisted by a familiar verb)
Number of subjects: 0
Study: 15050908

Group type: EXPERIMENTAL
Intervention: High-impact circuit intervention (12 min, three times a week) for 20 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (33 maturity-matched boys)
Number of subjects: 31
Study: 12383664

Group type: EXPERIMENTAL
Intervention: Stent-assisted PCI
Number of subjects: 988

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 988
Study: 9830258

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 22

Group type: COMPARATOR
Intervention: typical antipsychotic medication
Number of subjects: 22
Study: 7973751

Group type: EXPERIMENTAL
Intervention: Conservative and functional treatment with AIRCAST pneumatic leg braces, including a lower leg cast for 2 weeks followed by mobilization with protection from the brace.
Number of subjects: 29
Study: 2689314

Group type: EXPERIMENTAL
Intervention: Pulmo-Timelets (600 mg theophylline)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theophylline controlled-release tablet (600 mg theophylline)
Number of subjects: 12
Study: 30366361

Group type: EXPERIMENTAL
Intervention: Genetically predicted circulating vitamin K₁ levels (per 1 nmol/L increase)
Number of subjects: 34217
Study: 26822714

Group type: EXPERIMENTAL
Intervention: UC‐II (40 mg daily)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191

Group type: COMPARATOR
Intervention: GC (1500 mg G & 1200 mg C)
Number of subjects: 191
Study: 23681502

Group type: EXPERIMENTAL
Intervention: Combined 'whole muscle' training (resistance + aerobic) and inspiratory muscle training (IMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 20
Study: 23837717

Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation (TSF) sessions
Number of subjects: 32
Study: 20542554

Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg per day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 19025919

Group type: EXPERIMENTAL
Intervention: Immunosuppression with basiliximab and cyclosporine without prednisone (NoSt group)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Immunosuppression with basiliximab and cyclosporine with prednisone (St group)
Number of subjects: 89
Study: 16085238

Group type: EXPERIMENTAL
Intervention: Aggressive combined modality treatment arm for patients with poor prognosis
Number of subjects: 738

Group type: COMPARATOR
Intervention: Tamoxifen only
Number of subjects: 738

Group type: COMPARATOR
Intervention: Surgery with radiotherapy to the axilla
Number of subjects: 738

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 738
Study: 14989462

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with agalsidase alfa for 6 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 15
Study: 10579146

Group type: EXPERIMENTAL
Intervention: Sirolimus administered after a high-fat meal (15 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sirolimus administered while fasting (15 mg single dose)
Number of subjects: 0
Study: 9103685

Group type: EXPERIMENTAL
Intervention: Millet porridge
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: White rice
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: English potatoes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cereals (including millet and maize meal)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: English potatoes, maize meal, millet, and cassava
Number of subjects: 15
Study: 1899644

Group type: EXPERIMENTAL
Intervention: Continuous release transdermal nitroglycerin (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Discontinuous release transdermal nitroglycerin (group 2)
Number of subjects: 30
Study: 6179617

Group type: EXPERIMENTAL
Intervention: Anthracyclines (daunomycin and Adriamycin)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Adriamycin during induction of remission and maintenance therapy
Number of subjects: 306
Study: 31476539

Group type: COMPARATOR
Intervention: Buccal‐based triangular flap (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lingual‐based triangular flap (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 31522612

Group type: EXPERIMENTAL
Intervention: Anti-legalisation message
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pro-legalisation message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-NC participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-NC participants
Number of subjects: 0
Study: 28322356

Group type: EXPERIMENTAL
Intervention: Motivational interviewing and caries risk assessment (MICRA programme)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Routine programme
Number of subjects: 214
Study: 27481909

Group type: EXPERIMENTAL
Intervention: Postural exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neck support pillow
Number of subjects: 0
Study: 23506407

Group type: EXPERIMENTAL
Intervention: Immediate loading of four dental implants with a fixed prosthesis (experimental arm)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional loading technique (control arm)
Number of subjects: 45
Study: 22832126

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 66 µg/kg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 40
Study: 19650603

Group type: EXPERIMENTAL
Intervention: Oral-B Advantage 123
Number of subjects: 50

Group type: COMPARATOR
Intervention: Colgate 360 degrees
Number of subjects: 50
Study: 17384406

Group type: EXPERIMENTAL
Intervention: Community-focused intervention tools (neighborhood assessment with tip sheets and community resource guide)
Number of subjects: 0
Study: 15679573

Group type: EXPERIMENTAL
Intervention: Power training for 15 weeks
Number of subjects: 23
Study: 12412826

Group type: EXPERIMENTAL
Intervention: Zomacton 4 mg/ml conventional syringe administration (Treatment A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zomacton 10 mg/ml conventional syringe administration (Treatment B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zomacton 10 mg/ml ZomaJet 2 Vision administration (Treatment C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZomaJet 2 Vision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacodynamic profiles (IGF-1 and FFA)
Number of subjects: 0
Study: 10212734

Group type: EXPERIMENTAL
Intervention: Combination of emotional, organic and neuropsychological measures (Hospital Anxiety and Depression Scale, Impact of Event Scale, Short Orientation Memory and Concentration Test, Rivermead Post‐Concussion Symptoms Questionnaire, Post‐Traumatic Amnesia) taken at 7‐10 days post-injury
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale, Impact of Event Scale, Post‐Traumatic Amnesia
Number of subjects: 57
Study: 7597114

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.0 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lorazepam 2.0 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1983412

Group type: EXPERIMENTAL
Intervention: Ranitidine 150mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Famotidine 20mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nizatidine 150mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6109235

Group type: EXPERIMENTAL
Intervention: Floctaphenine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Acetylsalicylic Acid (ASA)
Number of subjects: 98
Study: 30222484

Group type: EXPERIMENTAL
Intervention: 27-Hz vibration condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10-Hz vibration condition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control condition (0-Hz frequency)
Number of subjects: 18
Study: 30385451

Group type: EXPERIMENTAL
Intervention: Finger prick autologous blood (FAB) treatment
Number of subjects: 60
Study: 26542271

Group type: EXPERIMENTAL
Intervention: PT (Physical Therapy) 3 times/week for 4 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: PT combined with MLD (Manual Lymphatic Drainage) 5 times/week for 4 weeks
Number of subjects: 41
Study: 25138681

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch applied to buttocks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch applied to outer upper arm
Number of subjects: 43

Group type: COMPARATOR
Intervention: Transdermal contraceptive patch applied to lower abdomen
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch applied to any site
Number of subjects: 43
Study: 22732964

Group type: EXPERIMENTAL
Intervention: Lupinus mutabilis
Number of subjects: 2

Group type: COMPARATOR
Intervention: Soy (control)
Number of subjects: 2
Study: 19908948

Group type: EXPERIMENTAL
Intervention: Carisoprodol 250 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Carisoprodol 350 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 17548761

Group type: EXPERIMENTAL
Intervention: Multicomponent health promotion intervention program
Number of subjects: 978

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 978
Study: 15378438

Group type: EXPERIMENTAL
Intervention: Tafenoquine 400 mg (base) daily for 3 days, followed by single monthly 400-mg doses (n = 104)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo (n = 101)
Number of subjects: 205
Study: 11162345

Group type: EXPERIMENTAL
Intervention: Minimal contact behavioral intervention using the Stage‐of‐Change concept
Number of subjects: 530

Group type: COMPARATOR
Intervention: Usual treatment condition
Number of subjects: 530
Study: 10186498

Group type: EXPERIMENTAL
Intervention: Young subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experience
Number of subjects: 0
Study: 7976902

Group type: EXPERIMENTAL
Intervention: 3D TOF MR angiography (MPR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2D TOF MR angiography (MIPs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MOTSA MR angiogram
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intraarterial angiography
Number of subjects: 20
Study: 2485152

Group type: EXPERIMENTAL
Intervention: Cyclooxygenase inhibitors (azapropazone) and aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-steroidal antiphlogistic drugs
Number of subjects: 0
Study: 1148993

Group type: EXPERIMENTAL
Intervention: Low-dose preoperative irradiation (2000-2500 rads/10 fractions/12 days)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Higher dose preoperative irradiation (3150 rads)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (no irradiation)
Number of subjects: 700